Marianna Chavdarova Semenistaia

Marianna Chavdarova Semenistaia

Auto-generated profile, based on publicly available information

Marianna Chavdarova Semenistaia

Medical University of Sofia, Sofia, Bulgaria; University Specialized Orthopaedic Hospital “Prof. B. Boychev”, Sofia, Bulgaria

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2018 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
CPChavdar Pavlov
Chavdar Pavlov
ДВДарья Леонидовна Варганова
Дарья Леонидовна Варганова
MSMarianna C. Semenistaia
Marianna C. Semenistaia
EKEkatherina A. Kuznetsova
Ekatherina A. Kuznetsova
АУАнна Александровна Усанова
Анна Александровна Усанова
ЕКЕкатерина Алевтиновна Кузнецова
Екатерина Алевтиновна Кузнецова
Вackground: Non-alcoholic liver disease (NAFLD) is a widely spread disease that needs an effective and safe treatment strategy. One of pharmacological treatments for people with NAFLD is ursodeoxycholic acid (UDCA). The use of UDCA is pathogenetically justified because of its cytoprotective, antiapoptotic, antioxidant, and hypoglycemic properties. Aim: Our meta-analysis (M-A) aimed to assess the benefits and harms of UDCA in people with NAFLD. Material and methods: We identified trials through electronic searches in the Cochrane Hepato-Biliary (CHB) Controlled Trials Register, CENTRAL, MEDLINE, Embase, SCI, LILACS, eLibrary (May 2018). We considered for inclusion randomised clinical trials (RCTs) assessing URSO versus placebo/no intervention in adult participants with NAFLD. We allowed co-interventions in the trial groups if they were similar. We followed Cochrane methodology, CHB Group methodology using Review Manager 5 and Trial Sequential Analysis to perform meta-analysis (M-A), assessed bias risk of the trials, quality of evidence using GRADE. Results: Four RCT, at high bias risk, low quality of evidence, provided data for analysis: 254 participants at different stages of NAFLD received oral UDCA (median of 18 months), 256 ― placebo/no intervention; age 18 to 75 years. We found no evidence of effect on mortality (there were no deaths) and on histological parameters such as steatosis (MD -0.13; CI -0.40−0.13; participants 323; trials 3; I2=43%), fibrosis (MD 0.00; CI -0.00−0.22; participants 323; trials 3; I2=0%), and inflammation (MD -0.05; CI -0.20−0.10; participants 325; trials 3; I2=0%). Also we found no evidence for significant influence of UDCA on occurrence of serious adverse events (RR 1.45, 95% CI 0.65−3.21; participants 292; trials 2; I2=0%), adverse events (RR 1.52, 95% CI 0.73−3.16; participants 510; trials 4; I2=36%) neither with traditional M-A (random-effects), nor with TSA SAE (CI 0.56−2.91; participants 292; trials 2; I2=0%, D2=0%), AE (CI 0.77–2.21; participants 510; trials 4; I2=0%, D2=0%). There was no evidence of effect on cytolysis, but beneficial effect of UDCA on cholestasis (GGTP) (data from two trials only) (р0.0001). We found no data on quality of life. All the trials were funded by the industry. Conclusion: Based on the small number of trials at high risk of bias, low quality, despite the safety profile observed with our M-A, we can neither recommend nor reject the use of UDCA for people with NAFLD. Further trials with low risk of bias and high quality are required to assess the benefits and harms of UDCA.

19 November 2021 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
DTD. A. Teplyuk
D. A. Teplyuk
MSM. Ch. Semenistaya
M. Ch. Semenistaya
SSS. M. Sorokoletov
S. M. Sorokoletov
LLL. B. Lazebnik
L. B. Lazebnik
CPChavdar Pavlov
Chavdar Pavlov
Nonalcoholic fatty liver disease (NAFLD) is a disease which etiology is related to various metabolic, ethnic, genetic and even ecologic factors. Complexity of etiology and multiply pathogenesis ways, leading eventually to the lipid droplets appearance in hepatocytes, infl ammation process and parenchyma fi brosis in liver, and also frequent cardiometabolic comorbidities, together make diffi cult risks stratifi cation and prognosis evaluation in NAFLD patients. Another matter is a question of NAFLD therapy, since unifi ed pharmacotherapy approaches are not yet adopted worldwide, and lifestyle modifi cation being accepted as an eff ective therapeutic approach, is not followed by patients in real world setting. Current review is dedicated to the consideration of NAFLD diagnostics, its risk of progression and existing therapeutical capabilities.

10 November 2025 in Traumatology and Orthopedics of Russia
Verified
Journal Article
Open access
PDF file
MSMarianna Chavdarova Semenistaia
Marianna Chavdarova Semenistaia
BCBorislav Chongov
Borislav Chongov
ASAnton A. Semenistyy
Anton A. Semenistyy
Background. The impact of regular sports activities and specific types of sports on the effectiveness of conservative treatment for adolescent idiopathic scoliosis (AIS) has not been sufficiently studied. Understanding this relationship is essential for personalizing programs of physiotherapeutic specific scoliosis exercises (PSSE) and preventing deformity progression. The aim of the study — to compare the results of conservative therapy for adolescent idiopathic scoliosis among rhythmic gymnasts, swimmers, and patients not engaged in regular sports activities, as well as to evaluate the influence of sport type on changes in frontal and sagittal trunk balance parameters and flexibility. Methods. A retrospective analysis was performed on 54 patients: 21 rhythmic gymnasts (Group 1), 11 swimmers (Group 2), and 22 non-athletic patients (Group 3, control). The groups were comparable in terms of key anthropometric and radiological parameters. All patients underwent PSSE according to the BSPTS Rigo method. TLSO bracing was used when indicated. Before and after treatment, the Cobb angle, thoracic kyphosis, lumbar lordosis, sagittal index, angle of trunk inclination (ATI), and flexibility (sit-and-reach test) were assessed. Results. Significant intergroup differences were found only for the Cobb angle (H = 9.366; p = 0.007) during treatment. Post-hoc analysis revealed that gymnasts showed a statistically significantly greater reduction in Cobb angle compared with the control group (p 0.0167). Differences between the control group and swimmers, as well as between gymnasts and swimmers, did not reach statistical significance after adjustment. No significant intergroup differences were found for other parameters (thoracic kyphosis, lumbar lordosis, sagittal index, flexibility, body mass, and height). Intragroup analysis demonstrated a statistically significant decrease in Cobb angle and ATI among gymnasts, and improved flexibility in both gymnasts and the control group. Deformity progression greater than 5° occurred less frequently in athletes (3.1%) than in non-athletic patients (27.3%; p = 0.0144). Conclusion. Conservative treatment based on physiotherapeutic specific scoliosis exercises is effective in all patients with adolescent idiopathic scoliosis. Rhythmic gymnasts demonstrated a more pronounced correction of frontal plane deformity and a greater reduction in trunk inclination compared with non-athletic patients. Swimming did not show advantages for correction of deformities in either the frontal (Cobb angle) or sagittal (lordosis, kyphosis) planes.

1 October 2025 in Translational Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
TTTaisiia Turankova
Taisiia Turankova
PRPhilipp Roshchin
Philipp Roshchin
DBDina Baimukhambetova
Dina Baimukhambetova
OMOleg Mestnikov
Oleg Mestnikov
NMNadezhda Moroz
Nadezhda Moroz
CPChavdar Pavlov
Chavdar Pavlov
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common form of chronic liver disease, found in more than a quarter of the world’s population. People with MASLD are at a high risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The risk of a mild cold turning into severe pneumonia is also high. The aim of our study was to evaluate the effect of MASLD as a risk factor for the severity of coronavirus disease-associated pneumonia (COVID-AP). Methods: Our prospective, Russian cohort study included 100 adults (≥18 years old), of any sex, with COVID-AP. The SARS-CoV-2 infection was confirmed on nucleic acid amplification or using the SARS-CoV-2 antigen tests. Any possible secondary causes of liver steatosis were excluded, and alcohol consumption was assessed. The presence of significant hepatic steatosis (more than 30%) was estimated from computed tomography (CT) results. Results: Based on the presence of significant steatosis, in combination with other metabolic factors, two groups were formed: 25 patients with MASLD and 74 patients without significant steatosis, serving as controls. One patient was excluded from the MASLD group due to alcohol abuse. The two groups were comparable by sex (P=0.58) and age (P=0.96). Body mass index (BMI) (P<0.001), waist circumference (P<0.001), and obesity rate (P=0.001) were significantly higher in the MASLD group. Presence of hypertension (HTN) (P=0.52) and type 2 diabetes mellitus (T2DM) (P=0.06) were comparable in the two groups. Based on the initial higher volume of lung damage upon admission (P=0.04), an increase in lung damage during standard glucocorticosteroid therapy and an anticoagulant drug (P=0.01), the higher levels level of C-reactive protein (P=0.01), and the need for biological therapy, pneumonia in the MASLD group was more severe compared with the control group. The relationship between the biological therapy and metabolic factors variables had an odds ratio (OR) of 11.4; P<0.001 for hepatic steatosis and of 2.3; P=0.046 for obesity. No association with T2DM (P=0.61) and HTN was found (P=0.76). To eliminate the possible interaction between obesity and hepatic steatosis, the Mantel-Hensel test was used. The adjusted OR for steatosis was 10.2; P=0.001 and for obesity the OR was 1.39; P=0.49. The need for antibiotic therapy was associated with the significant presence of steatosis (OR =3.1; P=0.02) and T2DM (OR =6.8; P=0.008), adjusted OR for steatosis was 2.6; P=0.057. The duration of hospitalisation between the two groups was comparable (P=0.07). Mortality was significantly increased in the MASLD group (P=0.02). Conclusions: Liver steatosis, regardless of other metabolic risk factors, increased the need for biological therapy, whereas the need for antibiotic therapy was a consequence of T2DM. Our study showed a more severe course of COVID-AP in people with MASLD and higher mortality.